Abstract:Atherosclerosis is the leading cause of death in western countries. Lipoprotein metabolism is closely related with the disease. ApoB-containing lipoproteins (BLp) are atherogenic particles, while, high density lipoproteins (HDL) are anti-atherogenic. Phospholipids Transfer Protein (PLTP) activity has important impact on BLp and HDL homeostasis. Animal studies, including general knock out (KO) and transgenic approaches, have shown pro-atherogenic properties for PLTP. However, the tissue specific function of PLTP remains mostly unknown. To address the impact of liver-specific expression of PLTP on lipoprotein metabolism, we have created two mouse models which either express PLTP specifically in the liver on a PLTP-null background or do not express PLTP in the liver (liver-specific PLTP KO) in a wild type background. In both models, our findings show that liver-specific PLTP is responsible for 25-30% of total plasma PLTP activity. Moreover, liver-specific PLTP expression model shows a remarkable increase in plasma levels of BLp, whereas liver-specific PLTP KO mice show significant reduction of BLp in plasma in compare to control group. These results further show the significant contribution of PLTP in BLp production. We also found that HDL levels are slightly increased in the first model, while in liver-specific PLTP KO animals HDL levels are significantly decreased. In order to unravel the mechanism, we evaluated the apoB and triglyceride production rates after blocking the clearance of the particles. We found that liver-specific PLTP increases apoB (both apo48 and apoB100) and triglyceride (TG) secretion rates. Additionally, the study of the hepatocyte microsomal luminal content lipidation in the first model showed that in the presence of PLTP BLp lipidation, which reflects as higher level of TG in microsomal luminal content, is significantly higher than the control group. Our results indicate that liver-generated PLTP promotes atherogenic lipoprotein production and provides a rationale for liver-specific PLTP inhibition as a therapeutical approach for the treatment of atherosclerosis.

Anti-inflammatory effects of phospholipid transfer protein (PLTP) deficiency in mice.

PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity

The Binding Capability of Plasma Phospholipid Transfer Protein, but Not Hdl Pool Size, is Critical to Repress Lps Induced Inflammation

Macrophage Phospholipid Transfer Protein Contributes Significantly To Total Plasma Phospholipid Transfer Activity And Its Deficiency Leads To Diminished Atherosclerotic Lesion Development

Increased Atherosclerotic Lesions in ApoE Mice with Plasma Phospholipid Transfer Protein Overexpression

Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency

The Effect of Phospholipid Transfer Protein on Lipoprotein Metabolism and Atherosclerosis

Abstract 330: Liver-Specific Phospholipids Transfer Protein Activity Has Significant Contribution in Hepatocyte Apob-Containing Lipoprotein Production and in Plasma Lipoprotein Metabolism

Effect of phospholipid transfer protein on plasma sphingosine-1-phosphate

Inducible phospholipid transfer protein deficiency ameliorates atherosclerosis

Abstract 19705: PLTP Deficiency Attenuates High Fat Diet Induced Obesity and Insulin Resistance

Phospholipid Transfer Protein Destabilizes Mouse Atherosclerotic Plaque.

Phospholipid Transfer Protein Deficiency Protects Circulating Lipoproteins from Oxidation Due to the Enhanced Accumulation of Vitamin E

Disruption of Phospholipid Transfer Protein-Mediated High-Density Lipoprotein Maturation Reduces Scavenger Receptor BI Deficiency-Driven Atherosclerosis Susceptibility Despite Unexpected Metabolic Complications

Effect of Plasma Phospholipid Transfer Protein Deficiency on Lethal Endotoxemia in Mice

Phospholipid Transfer Protein (Pltp) Deficient Mice Absorb Less Cholesterol

Macrophage Phospholipid Transfer Protein Deficiency and ApoE Secretion

Targeted Mutation of Plasma Phospholipid Transfer Protein Gene Markedly Reduces High-Density Lipoprotein Levels.

Phospholipid Transfer Protein (PLTP) Deficiency Attenuates High Fat Diet Induced Obesity and Insulin Resistance.

Liver-Specific Phospholipid Transfer Protein Deficiency Reduces High-Density Lipoprotein and Non–High-Density Lipoprotein Production in Mice

Phospholipid Transfer Protein Deficiency Impairs Apolipoprotein-B Secretion from Hepatocytes by Stimulating a Proteolytic Pathway Through a Relative Deficiency of Vitamin E and an Increase in Intracellular Oxidants*